Honjo Megumi

Shimizu Shota, Nemoto Hotaka, Ohata Shunichiro, Aihara Makoto, Honjo Megumi

MLT lowered IOP in rabbits by increasing outflow facility through transient MMP upregulation and ECM remodeling in the trabecular meshwork, elucidating its therapeutic mechanism for glaucoma.

Sato Minayo, Sakata Rei, Yamae Teruki, Suzuki Haruyuki, Nemoto Hotaka, Saito Hitomi et al.

PreserFlo MicroShunt safely and effectively reduced IOP and medication in Japanese glaucoma patients with prior surgery (filtration or ab interno/laser), offering a valuable option for complex cases.

Akiyama Kaho, Aoki Shuichiro, Shirato Shiroaki, Sakata Rei, Honjo Megumi, Aihara Makoto et al.

This study found eyes with unilateral peripapillary intrachoroidal cavitation (PICC) have distinct, elongated optic nerve head structures compared to fellow eyes, suggesting a strong link to myopia-related remodeling.

Shimizu Shota, Honjo Megumi, Liu Mengxuan, Aihara Makoto

Researchers developed a mouse model where autotaxin overexpression caused sustained high eye pressure via angle fibrosis, leading to retinal ganglion cell loss. This provides a new, inflammation-free model for glaucoma research.

Goto Hiroki, Honjo Megumi, Omoto Takashi, Aihara Makoto

Combined cataract surgery and trabeculotomy was effective, but long axial length eyes showed less IOP reduction and higher early IOP spikes, indicating a need for closer monitoring in these patients.

Aoyama Yurika, Sakata Rei, Fujishiro Takashi, Honjo Megumi, Shirato Shiroaki, Aihara Makoto

Ex-PRESS drainage achieved good IOP control in glaucoma patients, but late bleb needling significantly predicted poorer long-term IOP outcomes, suggesting caution with this intervention.

Akiyama Kaho, Saito Hitomi, Shirato Shiroaki, Iwase Aiko, Aoki Shuichiro, Sugimoto Koichiro et al.

This study found that in early glaucoma with high myopia, circumpapillary vessel density (cpVD) correlates strongly with visual function and is less affected by axial length than RNFL thickness, offering a potentially more reliable diagnostic marker.

Nemoto Hotaka, Honjo Megumi, Okamoto Michiaki, Sugimoto Koichiro, Aihara Makoto

MP-CPC in rabbits reduced IOP by increasing uveoscleral outflow, possibly via MMP upregulation, suggesting a mechanism for this glaucoma treatment.

Yamagishi-Kimura Reiko, Honjo Megumi, Aihara Makoto

This study found a new glaucoma drug (sepetaprost) lowers eye pressure longer than latanoprost, likely by increasing fluid outflow through both FP and EP3 receptors, offering a potential long-acting treatment.

Aoyama Yurika, Sakata Rei, Fujishiro Takashi, Honjo Megumi, Shirato Shiroaki, Aihara Makoto

Ex-PRESS glaucoma surgery caused a small, non-problematic CECD decrease (1.8%/year) over 3 years, but patients with low preoperative CECD need regular monitoring for potential future issues.

Nakajima Kosuke, Sakata Rei, Ueda Koji, Fujita Asahi, Fujishiro Takashi, Honjo Megumi et al.

Trabeculectomy in NTG patients with low preoperative IOP significantly slowed central visual field deterioration, suggesting it can preserve central vision even in these challenging cases.

Igarashi Nozomi, Honjo Megumi, Kaburaki Toshikatsu, Aihara Makoto

ROCK inhibitors attenuated CMV-induced corneal endothelial cell apoptosis and barrier dysfunction in Posner-Schlossman syndrome. This suggests ROCK inhibition could protect corneal cells in these patients.

Yamagishi-Kimura Reiko, Honjo Megumi, Komizo Takashi, Ono Takashi, Yagi Akiko, Lee Jinhee et al.

This study found pilocarpine interfered with ripasudil's IOP-lowering effects by altering outflow pathway cells. Clinically, combining these glaucoma drugs may reduce ripasudil's efficacy.

Honjo Megumi, Igarashi Nozomi, Kurano Makoto, Yatomi Yutaka, Igarashi Koji, Kano Kuniyuki et al.

Aqueous humor ATX/LPA levels were studied across glaucoma types, finding they are elevated in glaucoma, correlate with IOP, and vary by subtype, suggesting their role in IOP regulation and glaucoma pathogenesis.

Honjo Megumi, Igarashi Nozomi, Nishida Junko, Kurano Makoto, Yatomi Yutaka, Igarashi Koji et al.

This study found dexamethasone increases ATX-LPA pathway activity in TM cells, driving fibrotic changes. Inhibiting this pathway reduced these effects, suggesting it's a potential therapeutic target for glaucoma.

Uchida Takatoshi, Honjo Megumi, Yamagishi Reiko, Aihara Makoto

Ripasudil, a glaucoma drug, was studied in rats with induced uveitis. It significantly reduced inflammation markers and cell infiltration, suggesting it could treat ocular inflammatory diseases like uveitis and potentially uveitic glaucoma.

Aoyama-Araki Yuka, Honjo Megumi, Uchida Takatoshi, Yamagishi Reiko, Kano Kuniyuki, Aoki Junken et al.

After glaucoma surgery, S1P levels increase, activating conjunctival fibroblasts via S1P2 receptors, promoting scarring. S1P2 antagonists may prevent this scarring, improving surgical outcomes.

Kameda Takanori, Inoue Toshihiro, Inatani Masaru, Fujimoto Tomokazu, Honjo Megumi, Kasaoka Nanako et al.

ROCK inhibitor Y-27632 increased aqueous outflow by disrupting Schlemm's canal cell junctions and actin, improving glaucoma drainage.

Hirata Akira, Inatani Masaru, Inomata Yasuya, Yonemura Naoko, Kawaji Takahiro, Honjo Megumi et al.

Y-27632, a ROCK inhibitor, protected retinal cells from ischemia-induced death by reducing inflammation, suggesting a neuroprotective glaucoma therapy.

Honjo Megumi, Tanihara Hidenobu, Kameda Takanori, Kawaji Takahiro, Yoshimura Nagahisa, Araie Makoto

Y-27632, a ROCK inhibitor, was studied for glaucoma surgery scarring. It inhibited human fibroblast activity and reduced scarring in rabbits, suggesting it could be an effective anti-scarring agent for filtration surgery.